C
Christian Münz
Biochemist
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
NOV 2
Jul 15, 2026
Jan D Lünemann and Christian Münz on Epstein–Barr virus and multiple sclerosis
3:21
3:27
3:47
4:03
4:13
8:33

Heather BrownHOST
And you mentioned this a bit, but what have we learnt in recent years about the mechanisms that link EBV to MS?

Christian MünzGUEST
So the main, uh, four mechanisms that are currently discussed for this link between Epstein-Barr virus and MS, EBV being sort of a condition sine qua non for starting maybe the prodromal, uh, MS pathogenesis, are four main mechanisms.

Christian MünzGUEST
Uh, it is, uh, thought that EBV-specific immune responses, either humoral immune responses at the antibody level or at the T cell level, cross-react between EBV antigens and autoantigens of the central nervous system.

Christian MünzGUEST
Therefore, EBV infection would start these misguided immune responses that then would, uh, target structures in the central nervous system.

Christian MünzGUEST
There's a second mechanism that suggests that, uh, EBV converts B cells into a phenotype, um, so-called H-associated or ABC B cells that, um, migrate to the central nervous system and start an inflammation in this tissue, recruiting other immune cells, and therefore establishing an inflammation that continues then to drive the disease process.

Heather BrownHOST
How might what we know about EBV and MS be used to treat or even prevent MS, and how close are we to making that a reality?